

Application No: 09/522,753
Filing Date: March 10, 2000
Response to Office Action (mailed September 22, 2006)
Page 3 of 13

Attorney Docket No: SALK 1510-3
(088802-8704)

RECEIVED
CENTRAL FAX CENTER
DEC 20 2006

Amendments to the Claims/Listing of Claims

Please amend claims 3-5, 14, 23, and 25 and cancel claim 24 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1.- 2. (Cancelled)
3. (Currently amended) The polynucleotide of claim 4, wherein the SMRT co-repressor comprises a repression domain having
 - a) less than ~~about~~ 83% identity with a Sin3A interaction domain of N-CoR set forth as amino acids 255 to 312 of SEQ ID NO: 11;
 - b) less than ~~about~~ 57% identity with repression domain 1 of N-CoR set forth as amino acids 1 to 312 of SEQ ID NO: 11;
 - c) less than ~~about~~ 66% identity with a SANT domain of N-CoR set forth as amino acids 312 to 668 of SEQ ID NO: 11; or
 - d) less than ~~about~~ 30% identity with repression domain 2 of N-CoR set forth as amino acids 736 to 1031 of SEQ ID NO: 11.
4. (Currently amended) An isolated polynucleotide encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor), ~~or a peptide portion thereof~~, or an isolated polynucleotide complementary thereto, wherein said SMRT co-repressor ~~or peptide portion thereof~~ is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors, and wherein the amino acid sequence of said SMRT co-repressor ~~or peptide portion thereof~~ comprises ~~an~~ the amino acid sequence of having at least 80% sequence identity with SEQ ID NO: 5 or conservative variations thereof.

OLMR_292248.1

Application No: 09/522,753
Filing Date: March 10, 2000
Response to Office Action (mailed September 22, 2006)
Page 4 of 13

Attorney Docket No: SALK 1510-3
(088802-8704)

5. (Currently amended) An isolated polynucleotide encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor), ~~or a peptide portion thereof~~, or an isolated polynucleotide complementary thereto, wherein said SMRT co-repressor ~~or peptide portion thereof~~ is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors, and wherein said polynucleotide has at least 80% sequence identity with SEQ ID NO: 4.

6.-13. (Cancelled)

14. (Currently amended) An isolated polynucleotide ~~encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor), or a peptide portion thereof~~, wherein said SMRT co-repressor ~~or peptide portion thereof~~ is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors, and wherein said polynucleotide is selected from the group consisting of:

(a) a polynucleotide encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor) wherein said SMRT co-repressor is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors and wherein said polynucleotide comprises a nucleotide sequence having at least 80% sequence identity with nucleotides 1 to 3094 of SEQ ID NO: 4, provided that the polynucleotide does not contain a sequence identical to SEQ ID NO: 11; and

(b) polynucleotides complementary to the sequence of (a)[[,]]
~~provided that the polynucleotide does not contain a sequence identical to SEQ ID NO: 11.~~

15. (Cancelled)

DLMR_292248.1

Application No: 09/522,753
Filing Date: March 10, 2000
Response to Office Action (mailed September 22, 2006)
Page 5 of 13

Attorney Docket No: SALK 1510-3
(088802-8704)

16. (Previously presented) A polynucleotide according to claim 14, wherein said polynucleotide is selected from the group consisting of:

- (a) nucleotides 1 to 3094 of SEQ ID NO: 4; and
- (b) polynucleotides having at least 80% sequence identity with the complementary sequence of (a).

17. (Cancelled)

18. (Previously presented) The polynucleotide of claim 5, comprising nucleotides 1 to 8561 of SEQ ID NO: 4.

19. (Previously presented) The polynucleotide of claim 4, which is operably linked to a second nucleotide sequence.

20. (Previously presented) The polynucleotide of claim 19, which encodes a fusion polypeptide comprising the SMRT co-repressor operably linked to a DNA binding domain of a transcription factor.

21. (Previously presented) A vector comprising the polynucleotide of claim 4.

22. (Previously presented) A host cell containing the polynucleotide of claim 4.

23. (Currently amended) An isolated oligonucleotide, comprising at least 15 nucleotides, that hybridizes, under ~~suitable~~ **high** stringency conditions, to the polynucleotide of claim 4, but does not hybridize to a polynucleotide encoding SEQ ID NO: 11 ~~or to a polynucleotide encoding an amino acid sequence consisting of amino acids 1031 to 2517 of~~

DLMR_292248.1

Application No: 09/522,753
Filing Date: March 10, 2000
Response to Office Action (mailed September 22, 2006)
Page 6 of 13

Attorney Docket No: SALK 1510-3
(088802-8704)

SEQ ID NO: 5, wherein the oligonucleotide encodes at least five contiguous amino acids of a sequence selected from the group consisting of:

amino acids 720 to 745 of SEQ ID NO: 5;

amino acids 716 to 742 of SEQ ID NO: 7; and

amino acids 497 to 523 of SEQ ID NO: 9.

24. (Cancelled)

25. (Currently amended) The oligonucleotide of claim 23, which hybridizes, under **suitable high** stringency conditions, to a polynucleotide encoding SEQ ID NO: 5 or SEQ ID NO: 7, but does not hybridize to a polynucleotide encoding SEQ ID NO: 9.

26.-38. (Cancelled)

DLMR_292248.1